J A Chan1, L S Blaszkowsky2, P C Enzinger3, D P Ryan2, T A Abrams3, A X Zhu2, J S Temel2, D Schrag3, P Bhargava3, J A Meyerhardt3, B M Wolpin3, P Fidias2, H Zheng4, S Florio5, E Regan5, C S Fuchs3. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital, Boston; Department of Hematology/Oncology, Harvard Medical School. Electronic address: jang@partners.org. 2. Department of Hematology/Oncology, Harvard Medical School; Division of Hematology/Oncology, Department of Medicine. 3. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital, Boston; Department of Hematology/Oncology, Harvard Medical School. 4. Department of Hematology/Oncology, Harvard Medical School; Biostatistics Center, Massachusetts General Hospital, Boston, USA. 5. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston.
Abstract
BACKGROUND: Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of esophageal and gastric carcinomas. Although previous studies have examined tyrosine kinase inhibitors of EGFR, there remains limited data regarding the role of EGFR-directed monoclonal antibody therapy in these malignancies. We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma. PATIENTS AND METHODS: Thirty-five patients with previously treated metastatic esophageal or gastric adenocarcinoma were treated with weekly cetuximab, at an initial dose of 400 mg/m(2) followed by weekly infusions at 250 mg/m(2). Patients were followed for toxicity, treatment response, and survival. RESULTS: Treatment with cetuximab was well tolerated; no patients were taken off study due to drug-related adverse events. One (3%) partial treatment response was noted. Two (6%) patients had stable disease after 2 months of treatment. Median progression-free survival and overall survival were 1.6 and 3.1 months, respectively. CONCLUSION: Although well tolerated, cetuximab administered as a single agent had minimal clinical activity in patients with metastatic esophageal and gastric adenocarcinoma. Ongoing studies of EGFR inhibitors in combination with other agents may define a role for these agents in the treatment of esophageal and gastric cancer.
BACKGROUND:Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of esophageal and gastric carcinomas. Although previous studies have examined tyrosine kinase inhibitors of EGFR, there remains limited data regarding the role of EGFR-directed monoclonal antibody therapy in these malignancies. We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma. PATIENTS AND METHODS: Thirty-five patients with previously treated metastatic esophageal or gastric adenocarcinoma were treated with weekly cetuximab, at an initial dose of 400 mg/m(2) followed by weekly infusions at 250 mg/m(2). Patients were followed for toxicity, treatment response, and survival. RESULTS: Treatment with cetuximab was well tolerated; no patients were taken off study due to drug-related adverse events. One (3%) partial treatment response was noted. Two (6%) patients had stable disease after 2 months of treatment. Median progression-free survival and overall survival were 1.6 and 3.1 months, respectively. CONCLUSION: Although well tolerated, cetuximab administered as a single agent had minimal clinical activity in patients with metastatic esophageal and gastric adenocarcinoma. Ongoing studies of EGFR inhibitors in combination with other agents may define a role for these agents in the treatment of esophageal and gastric cancer.
Authors: Tomislav Dragovich; Sheryl McCoy; Cecilia M Fenoglio-Preiser; Jiang Wang; Jacqueline K Benedetti; Amanda F Baker; Christopher B Hackett; Susan G Urba; Ken S Zaner; Charles D Blanke; James L Abbruzzese Journal: J Clin Oncol Date: 2006-10-20 Impact factor: 44.544
Authors: Y D Jung; P F Mansfield; M Akagi; A Takeda; W Liu; C D Bucana; D J Hicklin; L M Ellis Journal: Eur J Cancer Date: 2002-05 Impact factor: 9.162
Authors: Federico Rojo; Josep Tabernero; Joan Albanell; Eric Van Cutsem; Atsushi Ohtsu; Toshihiko Doi; Wasaburo Koizumi; Kuniaki Shirao; Hiroya Takiuchi; S Ramon y Cajal; S Ramon Cajal; José Baselga Journal: J Clin Oncol Date: 2006-09-10 Impact factor: 44.544
Authors: Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Derek J Jonker; Chris J O'Callaghan; Christos S Karapetis; John R Zalcberg; Dongsheng Tu; Heather-Jane Au; Scott R Berry; Marianne Krahn; Timothy Price; R John Simes; Niall C Tebbutt; Guy van Hazel; Rafal Wierzbicki; Christiane Langer; Malcolm J Moore Journal: N Engl J Med Date: 2007-11-15 Impact factor: 91.245
Authors: A Tokunaga; M Onda; T Okuda; T Teramoto; I Fujita; T Mizutani; T Kiyama; T Yoshiyuki; K Nishi; N Matsukura Journal: Cancer Date: 1995-03-15 Impact factor: 6.860
Authors: F Lordick; B Luber; S Lorenzen; S Hegewisch-Becker; G Folprecht; E Wöll; T Decker; E Endlicher; N Röthling; T Schuster; G Keller; F Fend; C Peschel Journal: Br J Cancer Date: 2010-01-12 Impact factor: 7.640
Authors: S-W Han; D-Y Oh; S-A Im; S R Park; K-W Lee; H S Song; N-S Lee; K H Lee; I S Choi; M H Lee; M A Kim; W H Kim; Y-J Bang; T-Y Kim Journal: Br J Cancer Date: 2009-01-06 Impact factor: 7.640
Authors: G Quintero Aldana; M Salgado; S Candamio; J C Méndez; M Jorge; M Reboredo; L Vázquez Tuñas; C Romero; M Covela; A Fernández Montes; M Carmona; Y Vidal Insua; R López Journal: Clin Transl Oncol Date: 2019-07-06 Impact factor: 3.405
Authors: Steven B Maron; Lindsay Alpert; Heewon A Kwak; Samantha Lomnicki; Leah Chase; David Xu; Emily O'Day; Rebecca J Nagy; Richard B Lanman; Fabiola Cecchi; Todd Hembrough; Alexa Schrock; John Hart; Shu-Yuan Xiao; Namrata Setia; Daniel V T Catenacci Journal: Cancer Discov Date: 2018-02-15 Impact factor: 39.397
Authors: Shumei Song; Soichiro Honjo; Jiankang Jin; Shih-Shin Chang; Ailing W Scott; Qiongrong Chen; Neda Kalhor; Arlene M Correa; Wayne L Hofstetter; Constance T Albarracin; Tsung-Teh Wu; Randy L Johnson; Mien-Chie Hung; Jaffer A Ajani Journal: Clin Cancer Res Date: 2015-03-04 Impact factor: 12.531
Authors: Felice Pasini; Anna Paola Fraccon; Yasmina Modena; Maria Bencivenga; Simone Giacopuzzi; Francesca La Russa; Milena Gusella; Giovanni de Manzoni Journal: Gastric Cancer Date: 2016-08-27 Impact factor: 7.370